Identification of human ccn2 (connective tissue growth factor) promoter polymorphisms
- 1 June 2001
- journal article
- Published by BMJ in Molecular Pathology
- Vol. 54 (3) , 192-196
- https://doi.org/10.1136/mp.54.3.192
Abstract
Connective tissue growth factor (CCN2; CTGF) is a newly identified growth factor, which is involved in the regulation of wound repair and fibrosis. Because there is variation among individuals with respect to tissue response to injury, genetic factors might be involved in the final outcome of tissue repair or scarring. For example, polymorphisms in the promoter region of genes, such as those encoding transforming growth factor beta1 (TGF-beta1), interleukin 10 (IL-10), and tumour necrosis factor alpha (TNF-alpha), influence transcriptional responses and are thought to contribute to the dysregulation of these genes in pathological conditions. To investigate whether the promoter region of the ccn2 (ctgf) gene contains polymorphic sequences that might account for differential expression. Seventy seven human DNA samples were sequenced-45 were from healthy controls and 32 were from patients with ischaemic heart disease (IHD)-using M13 tailed sequence specific ccn2 (ctgf) primers for amplification of a 600 bp fragment upstream of the transcription start site. Amplicons were bidirectionally sequenced with a dye primer M13 forward and reverse sequencing kit. A C to G substitution was identified at position -132 in one of the patients with IHD. Moreover, in five of the 32 patients with IHD and in six of the 45 healthy controls, a G to C polymorphism was found at position -447. These substitutions at -132 and -447 are thought to lie within predicted binding domains for the transcription factors Pbx-1 and MZF1, respectively. In addition, insertions at position -43 (G), -47 (C), -71 (G) and a C to T substitution at position -198 were found in all DNA samples compared with the published ccn2 (ctgf) promoter sequence. These corrections do not involve sequences predicted to function as transcription factor binding sites. Sequence analysis of the ccn2 (ctgf) promoter of 77 human DNA samples has revealed corrections and polymorphic sites. The latter lie within putative regulatory elements.Keywords
This publication has 33 references indexed in Scilit:
- CTGF and SMADs, Maintenance of Scleroderma Phenotype Is Independent of SMAD SignalingJournal of Biological Chemistry, 2001
- A Preliminary Study of Long-Term Treatment with Interferon Gamma-1b and Low-Dose Prednisolone in Patients with Idiopathic Pulmonary FibrosisNew England Journal of Medicine, 1999
- Expression of connective tissue growth factor in experimental rat and human liver fibrosisHepatology, 1999
- Cytokine gene polymorphism in human disease: on-line databasesGenes & Immunity, 1999
- Role and interaction of connective tissue growth factor with transforming growth factor-? in persistent fibrosis: A mouse fibrosis modelJournal of Cellular Physiology, 1999
- Suppression Subtractive Hybridization Identifies High Glucose Levels as a Stimulus for Expression of Connective Tissue Growth Factor and Other Genes in Human Mesangial CellsJournal of Biological Chemistry, 1999
- GENOTYPIC VARIATION IN THE TRANSFORMING GROWTH FACTOR-??1 GENETransplantation, 1998
- A novel transforming growth factor beta response element controls the expression of the connective tissue growth factor gene.1996
- Connective Tissue Growth Factor Gene Expression in Tissue Sections From Localized Scleroderma, Keloid, and Other Fibrotic Skin DisordersJournal of Investigative Dermatology, 1996
- Aberrant expression of the myeloid zinc finger gene, MZF-1, is oncogenic.1995